Literature DB >> 14994999

Outcome of incomplete systemic lupus erythematosus after 10 years.

C Ståhl Hallengren1, O Nived, G Sturfelt.   

Abstract

The objective was to identify cases of incomplete systemic lupus erythematosus (SLE) within a defined population in southern Sweden, risk factors for development of complete SLE (> or = 4 classification criteria) and study outcome of the patients. During prospective retrieval of SLE cases within a defined population in southern Sweden, 28 patients (26 women, two men) with incomplete SLE (< 4 ACR criteria) were identified between 1981 and 1992. All patient records were reviewed and clinical and laboratory data were extracted from standardized formats. Organ damage was defined according to the SLICC/ACR damage index. During follow-ups, 16 of 28 patients developed complete SLE (median 13 years; range 10-20 years). The time to develop complete SLE varied between one and ten years with a median time of 5.3 years. Three patients were anti-DNA positive at inclusion; only one of them developed complete SLE. False positive Wasserman reaction and anti-cardiolipin antibodies (aCl) were only found in patients who developed complete SLE (P < 0.04; Fisher exact test). Six patients had malar rash from the start and they all had complete SLE at follow-up (P < 0.04; Fisher exact test). Of eight patients with arthritis, three developed complete SLE. Thrombocytopenia was only found in two patients, both developing complete disease. At follow-up, patients that developed complete SLE had high SLICC damage scores (mean 1.5) compared with patients that remained as incomplete SLE (mean 0.16). In conclusion, in this follow-up study of patients with incomplete SLE 57% developed complete disease after a median time of 5.3 years. Malar rash and aCl were predictors of complete SLE. Individuals that developed complete SLE were more prone to organ damage.

Entities:  

Mesh:

Year:  2004        PMID: 14994999     DOI: 10.1191/0961203304lu477oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  22 in total

1.  Development of SLE among "potential SLE" patients seen in consultation: long-term follow-up.

Authors:  M Al Daabil; E M Massarotti; A Fine; H Tsao; P Ho; P H Schur; B L Bermas; K H Costenbader
Journal:  Int J Clin Pract       Date:  2014-05-23       Impact factor: 2.503

2.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; A E Wandstrat; F Carr-Johnson; V Branch; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 3.  Preclinical systemic lupus erythematosus.

Authors:  Julie M Robertson; Judith A James
Journal:  Rheum Dis Clin North Am       Date:  2014-09-02       Impact factor: 2.670

4.  Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.

Authors:  Melissa E Munroe; Rufei Lu; Yan D Zhao; Dustin A Fife; Julie M Robertson; Joel M Guthridge; Timothy B Niewold; George C Tsokos; Michael P Keith; John B Harley; Judith A James
Journal:  Ann Rheum Dis       Date:  2016-01-25       Impact factor: 19.103

5.  Prolidase deficiency breaks tolerance to lupus-associated antigens.

Authors:  Biji T Kurien; Anil D'Sousa; Benjamin F Bruner; Timothy Gross; Judith A James; Ira N Targoff; Jacen S Maier-Moore; Isaac T W Harley; Heng Wang; R Hal Scofield
Journal:  Int J Rheum Dis       Date:  2013-12-14       Impact factor: 2.454

6.  Organ damage in patients with incomplete lupus syndromes: from a Chinese academic center.

Authors:  Zhen Chen; Meng-Tao Li; Dong Xu; Xiao-Mei Leng; Qian Wang; Xin-Ping Tian; Shang-Zhu Zhang; Yan Zhao; Xiao-Feng Zeng
Journal:  Clin Rheumatol       Date:  2015-02-18       Impact factor: 2.980

7.  Screening characteristics for enrichment of individuals at higher risk for transitioning to classified SLE.

Authors:  K A Young; M E Munroe; J M Guthridge; D L Kamen; G S Gilkensen; J B Harley; M H Weisman; D R Karp; D J Wallace; J A James; J M Norris
Journal:  Lupus       Date:  2019-03-07       Impact factor: 2.911

8.  Interferon signature gene expression is correlated with autoantibody profiles in patients with incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; Y Lian; B Zhang; V K Branch; F Carr-Johnson; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2009-12-01       Impact factor: 4.330

9.  Organ damage in high-risk patients with systemic and incomplete lupus syndromes.

Authors:  Nancy J Olsen; Maha Yousif; Azza Mutwally; Melinda Cory; Nada Elmagboul; David R Karp
Journal:  Rheumatol Int       Date:  2013-05-30       Impact factor: 2.631

10.  Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus.

Authors:  T L Rivera; P M Izmirly; B K Birnbaum; P Byrne; J B Brauth; M Katholi; M Y Kim; J Fischer; R M Clancy; J P Buyon
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.